( e aresubstantial risks and uncertainti...)Study Suggests Strattera Improved ADHD Symptoms in Patients With,Comorbid Alcohol Abuse,Health

e are substantial risks and uncertainties in the process of development and commercialization, including the risk of side effects and other safety concerns. There is no guarantee that the product will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

    References

    (1) Marshal, MP, Molina, BSG, et al. "Attention-Deficit Hyperactivity

        Disorder Moderates the Life Stress Pathway to Alcohol Problems in

        Children of Alcoholics." Alcoholism: Clinical & Experimental Research.

        2007; 31:564-574:643-652.

    (2) Kessler, RC, Adler L, Barkley R, et al. "The Prevalence and Correlates

        of Adult ADHD in the United States: Results from the National

        Comorbidity Survey Replication." Am J Psychiatry. 163:4, April 2006.

    (3) National Institute of Mental Health. "NIMH research on treatment for

        attention-deficit hyperactivity disorder (ADHD): The multimodal

        treatment study - questions and answers." Available at:

        http://www.nimh.nih.gov/childhp/mtaqa.cfm. Accessed on March 13, 2007.

    (4) Pliszka SR, et al. Journal of the American Academy of Child and

        Adolescent Psychiatry. 1996., 35 (264-272).


    

CONTACT: Amy Sousa of Eli Lilly and Company, +1-317-276-8478 or+1-317-997-1481

Ticker Symbol: (:LLY)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

'"/>




Page: 1 2 3 4 5 6
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea